Trial reportAmerican journal of preventive medicine2017
PREVENT-DM Comparative Effectiveness Trial of Lifestyle Intervention and Metformin.
Trial report in American journal of preventive medicine, 2017. The graph read 1 number from its abstract, feeding 1 cell of the map: it . Cited by 42 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
RESULTS: ILI participants demonstrated significantly greater mean weight loss (-4.0 kg, 5.0%) than metformin (-0.9 kg, 1.1%) and standard care participants (+0.8 kg, 0.9%) (p<0.001).
clause the extractor read what became the number
Where it lands on the map
Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.
What it adds to each cell
For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.
Diet, exercise & lifestyle×body weight & composition
No readable resultOpen on the map →What to test next →3 readable studies in this cell: 2 favour the treatment, 0 find no difference, 1 favour the comparator.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 8 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Effects of pharmacological treatment and lifestyle modification on prediabetes: a systematic review and meta-analysis of randomized controlled trials (RCTS).Naunyn-Schmiedeberg's archives of pharmacology · 2026Pooled it
- Efficacy of lifestyle weight loss interventions on regression to normoglycemia and progression to type 2 diabetes in individuals with prediabetes: a systematic review and pairwise and dose-response meta-analyses.The American journal of clinical nutrition · 2024Pooled it
- Comparing the effectiveness of metformin with lifestyle modification for the primary prevention of type II diabetes: a systematic review and meta-analysis.BMC endocrine disorders · 2023 · on this mapPooled it
- A systematic review of inequalities in the uptake of, adherence to, and effectiveness of behavioral weight management interventions in adults.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2022Pooled it
- Interventions for Reversing Prediabetes: A Systematic Review and Meta-Analysis.American journal of preventive medicine · 2022 · on this mapPooled it
- Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2019 · on this mapPooled it
- Pooled it
- Pooled it
- Promotora intervention for metabolic and mental health to reduce type 2 diabetes risk: a pilot randomized controlled trial.Scientific reports · 2024Trial
- Effect of a Culturally Adapted Behavioral Intervention for Latino Adults on Weight Loss Over 2 Years: A Randomized Clinical Trial.JAMA network open · 2020Trial
- Effect of a family and interdisciplinary intervention to prevent T2D: randomized clinical trial.BMC public health · 2020Trial
- Effectiveness of a culturally adapted group-based lifestyle intervention in reducing cardiovascular risk factors in a high-risk Latin American population.Translational behavioral medicine · 2026Article
- Metformin Beyond Glycemic Control: Cardiovascular Protection and Diabetes Prevention.Journal of cardiovascular development and disease · 2026Review
- Meta-Analysis of the Effect of Metformin on the Progression of Different Types of Prediabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- Microbial perspective of multidisciplinary collaborative weight management approach:Gut microbes · 2025Article
- Prediabetes in acute stroke: prevalence and impact on early clinical outcomes.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- Matching implementation strategies to barriers and facilitators for a lifestyle front office in the hospital: a qualitative study.BMC health services research · 2025Article
- Metformin's Overall Effectiveness and Combined Action with Lifestyle Interventions in Preventing Type-2 Diabetes Mellitus in High-Risk Metformin-Naïve Patients: An Updated Systematic Review and Meta-Analysis of Published RCTs.Journal of clinical medicine · 2025Review
- Implementation of diabetes prevention programs into clinical practice and community settings: a systematic search and review.Implementation science communications · 2025Review
- Metabolic disorders in prediabetes: From mechanisms to therapeutic management.World journal of diabetes · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
The marked sentences are the ones the graph read a number from.
introductionAlthough the Diabetes Prevention Program and other clinical trials demonstrated the efficacy of intensive lifestyle interventions (ILI) and metformin to prevent type 2 diabetes, no studies have tested their comparative effects in pragmatic settings. This study was designed to compare the real-world effectiveness of ILI, metformin, and standard care among Hispanic women (Latinas) with prediabetes. STUDY
designRCT. SETTING/
participantsNinety-two Latinas, who had a mean hemoglobin A1c of 5.9%, BMI of 33.3 kg/m
interventionThe 12-month ILI was adapted from the Diabetes Prevention Program's ILI and delivered by community health workers (promotoras) over 24 sessions. Metformin participants received 850 mg twice daily. Those randomized to standard care continued their regular medical care.
main outcome measuresWeight and secondary outcomes (waist circumference, blood pressure, hemoglobin A1c, fasting plasma glucose, insulin, and lipids) were assessed at baseline and 12 months.
resultsILI participants demonstrated significantly greater mean weight loss (-4.0 kg, 5.0%) than metformin (-0.9 kg, 1.1%) and standard care participants (+0.8 kg, 0.9%) (p<0.001). The difference in weight loss between metformin and standard care was not significant. The ILI group experienced a greater reduction in waist circumference than standard care (p=0.001), and a marginal improvement in hemoglobin A1c compared with metformin and standard care (p=0.063).
conclusionsIn the first comparative effectiveness trial of diabetes prevention treatments, a 12-month ILI produced significantly greater weight loss than metformin and standard care among Latinas with prediabetes. These data suggest that ILI delivered by promotoras is an effective strategy for preventing diabetes in this high-risk group, which may be superior to metformin. Future pragmatic trials involving larger samples should examine differences in diabetes incidence associated with these treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.